On June 22, Axinn partner Jeny Maier participated in a webinar entitled, "Life Sciences Dealmaking Faces More Antitrust Scrutiny" hosted by Endpoints. 

The US Federal Trade Commission and other global regulators have stepped up antitrust enforcement in life sciences, most notably seeking to unwind Illumina’s $8 billion buyout of Grail. Other acquisitions, led by Amgen and Pfizer, have run into review or scrutiny. Participants examined the origins, impacts, and likely legacy of these antitrust policies.

Click here to access a video of the webinar.